Iain Stuart is CHIEF SCIENTIFIC OFFICER of VYNE Therapeutics Inc.. Currently has a direct ownership of 133,494 shares of VYNE, which is worth approximately $380,457. The most recent transaction as insider was on Sep 30, 2024, when has been sold 109 shares (Common Stock) at a price of $1.88 per share, resulting in proceeds of $204. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 133K
0.08% 3M change
1374.26% 12M change
Total Value Held $380,457

Iain Stuart Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 30 2024
SELL
Payment of exercise price or tax liability
$204 $1.88 p/Share
109 Reduced 0.08%
133,494 Common Stock
Jul 01 2024
SELL
Payment of exercise price or tax liability
$264 $1.92 p/Share
138 Reduced 0.1%
133,603 Common Stock
Apr 01 2024
SELL
Payment of exercise price or tax liability
$483 $3.08 p/Share
157 Reduced 0.12%
133,741 Common Stock
Jan 02 2024
SELL
Payment of exercise price or tax liability
$357 $2.28 p/Share
157 Reduced 0.12%
133,898 Common Stock
Jan 01 2024
BUY
Grant, award, or other acquisition
-
62,500 Added 31.8%
134,055 Common Stock
Dec 13 2023
BUY
Grant, award, or other acquisition
-
62,500 Added 46.62%
71,555 Common Stock
Oct 02 2023
SELL
Payment of exercise price or tax liability
$4,534 $3.83 p/Share
1,184 Reduced 11.56%
9,055 Common Stock
Jun 30 2023
SELL
Payment of exercise price or tax liability
$619 $4.1 p/Share
151 Reduced 1.45%
10,239 Common Stock
Mar 31 2023
SELL
Payment of exercise price or tax liability
$1,478 $3.08 p/Share
480 Reduced 4.42%
10,390 Common Stock
Dec 31 2022
SELL
Payment of exercise price or tax liability
$258 $0.15 p/Share
1,720 Reduced 0.77%
220,252 Common Stock
Sep 30 2022
SELL
Payment of exercise price or tax liability
$378 $0.22 p/Share
1,719 Reduced 0.77%
221,972 Common Stock
Jun 30 2022
SELL
Payment of exercise price or tax liability
$670 $0.39 p/Share
1,719 Reduced 0.76%
223,691 Common Stock
Mar 31 2022
SELL
Payment of exercise price or tax liability
$2,255 $0.65 p/Share
3,469 Reduced 1.52%
225,410 Common Stock
Mar 17 2022
BUY
Grant, award, or other acquisition
-
75,000 Added 24.68%
228,879 Common Stock
Dec 31 2021
SELL
Payment of exercise price or tax liability
$1,275 $1.02 p/Share
1,250 Reduced 0.81%
153,879 Common Stock
Sep 30 2021
SELL
Payment of exercise price or tax liability
$2,057 $1.39 p/Share
1,480 Reduced 0.95%
155,129 Common Stock
Sep 02 2021
BUY
Grant, award, or other acquisition
-
60,859 Added 27.99%
156,609 Common Stock
Jun 30 2021
SELL
Payment of exercise price or tax liability
$10,821 $3.51 p/Share
3,083 Reduced 3.12%
95,750 Common Stock
Mar 31 2021
SELL
Payment of exercise price or tax liability
$13,304 $6.84 p/Share
1,945 Reduced 1.93%
98,833 Common Stock
Feb 22 2021
BUY
Grant, award, or other acquisition
-
29,213 Added 22.47%
100,778 Common Stock
Dec 31 2020
SELL
Payment of exercise price or tax liability
$3,757 $1.58 p/Share
2,378 Reduced 0.82%
286,262 Common Stock
Sep 30 2020
SELL
Payment of exercise price or tax liability
$3,947 $1.66 p/Share
2,378 Reduced 0.82%
288,640 Common Stock
IS

Iain Stuart

CHIEF SCIENTIFIC OFFICER
Bridgewater, NJ

Track Institutional and Insider Activities on VYNE

Follow VYNE Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VYNE shares.

Notify only if

Insider Trading

Get notified when an Vyne Therapeutics Inc. insider buys or sells VYNE shares.

Notify only if

News

Receive news related to VYNE Therapeutics Inc.

Track Activities on VYNE